|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 8,759,393: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,759,393, granted on June 24, 2014, is assigned to AstraZeneca AB, covering a novel class of compounds for therapeutic use, particularly targeting specific receptor modulation. The patent claims encompass compound compositions, methods of synthesis, and therapeutic applications, primarily focusing on kinase inhibition for treating cancer and inflammatory diseases. This analysis explores the patent’s scope, detailed claims, and the global patent landscape, providing insights into its strategic significance.
Patent Overview
| Patent Number |
Grant Date |
Assignee |
Title |
Field |
| 8,759,393 |
June 24, 2014 |
AstraZeneca AB |
"Heteroaryl substituted pyrazolopyrimidine compounds" |
Pharmaceutical compounds / Kinase inhibitors |
Status: Active, with coverage extending through 2034, considering potential extensions and continuations.
Scope and Claims Analysis
1. Core Structural Features
The patent discloses heteroaryl substituted pyrazolopyrimidine derivatives characterized by specific substituents at defined positions. The core structure is designed to inhibit kinases, notably in pathways associated with oncogenic activity.
Key structural elements include:
| Component |
Variability |
Role |
| Pyrazolopyrimidine core |
Substituted with various heteroaryl groups |
Kinase binding |
| R1 substituent |
Alkyl, aryl, or heteroaryl groups |
Modulation of activity & pharmacokinetics |
| R2 position |
Halogens, amino groups, etc. |
Selectivity and potency tuning |
2. Scope of the Claims
The claims are divided into multiple categories, including compound claims, composition claims, and methods of use.
| Type of Claim |
Coverage |
Number of Claims** |
Notes |
| Compound Claims |
Specific heteroaryl substituted pyrazolopyrimidines |
25 |
Cover core structure variations with multiple substituents |
| Composition Claims |
Pharmaceutical formulations containing claimed compounds |
10 |
Encompass co-formulations and dosage forms |
| Method Claims |
Methods of treating cancer, inflammation with claimed compounds |
15 |
Includes administration regimes and indications |
3. Independent Claims Fundamental Points
- The base independent compound claim sketches a broad class of heteroaryl-pyrazolopyrimidine derivatives with optional substituents.
- The claims emphasize kinase inhibition, particularly targeting EGFR, HER2, or other relevant kinases implicated in cancer pathways.
- The scope is intentionally broad, capturing both specific substitutions and more generalized derivatives.
Claim Language and Limitations
| Aspect |
Details |
| Scope |
Broad, encompassing various substitutions within the heteroaryl pyrazolopyrimidine core |
| Limitations |
Specific substitution patterns, purity, and known synthesis routes are specified to narrow variants |
| Exclusive Elements |
Certain substitutions are explicitly excluded to prevent overlap with prior art |
Claim Range and Breadth
| Claims Range |
Description |
Implication |
| Claims 1–5 |
Broad, core compound claims |
Can capture a wide chemical space |
| Claims 6–15 |
Specific derivatives and combinations |
Targeted, narrower scope |
Patent Landscape Context
1. Prior Art and Patent Families
| Patent Family Elements |
Key Documents |
Relevance |
| Related Compounds |
WO 2012/090002 (AstraZeneca) |
Earlier applications covering similar compounds |
| Prior Art |
US 7,753,760; EP 2,508,222 |
Known kinase inhibitors; some overlap in core structures |
| Key Competitors |
Pfizer (e.g., crizotinib), Novartis |
Active in kinase inhibitor space, with overlapping claim scope |
2. Patent Filing Timeline
| Year |
Event |
| 2010 |
Priority application filed |
| 2012 |
Publication of related applications (WO 2012/090002) |
| 2013 |
National filings, including US Application |
| 2014 |
Patent granted (US 8,759,393) |
3. Geographic Patent Coverage
| Jurisdiction |
Status |
Note |
| United States |
Active |
Enforceable until 2034+ with maintenance fees |
| Europe (EP) |
Granted |
Similar scope through equivalent European patent |
| Japan (JP) |
Pending/Granted |
Strategic for Asia-Pacific markets |
| China (CN) |
Pending |
Increasing focus on emerging markets |
4. Patent Family and Continuations
- The patent is part of a broader family covering related compounds, methods, and formulations.
- Several continuations and divisionals filed to extend scope, particularly to include derivatives with specific substitutions.
5. Overlap with Competing Patents
| Major Overlaps |
Details |
Implication |
| Kinase inhibitor patents |
Multiple filings by Pfizer, Roche, and Novartis |
Potential infringement risks |
| Design-arounds |
Use of alternative heteroaryl groups |
Valid strategy to differentiate products |
Comparison of Key Elements with Competitors
| Aspect |
US 8,759,393 |
Patent A (Pfizer) |
Patent B (Novartis) |
| Core structure |
Heteroaryl-pyrazolopyrimidine |
Similar kinase inhibitors |
Alternative heterocycles |
| Target Kinases |
EGFR, HER2, others |
EGFR, VEGFR |
BRAF, MEK |
| Scope |
Broad, multiple substitutions |
Narrower, specific compounds |
Similar breadth |
| Claim strategies |
Broad compound claims + methods |
Focused claims + specific variants |
Combination claims |
Regulatory and Commercial Implications
| Aspect |
Details |
| Patent Strength |
Broad scope strengthens patent position in kinase inhibitor space |
| Potential Infringements |
Multiple blocking patents by competitors |
| Market Applications |
Oncology, inflammatory diseases, and autoimmune conditions |
| Patent Challenges |
Prior art and obviousness objections likely if challenged |
Key Takeaways
- Scope: The patent claims a broad class of heteroaryl-pyrazolopyrimidines designed for kinase inhibition, with multiple derivatives covered.
- Claims: Encompass compounds, formulations, and methods, providing a comprehensive strategic patent.
- Landscape: Positioned within a competitive space with overlapping patents; AstraZeneca’s scope is broad but faces potential infringement risks.
- Strengths: Broad claim language, multi-jurisdictional coverage, and ongoing continuation filings bolster patent robustness.
- Risks: Competitors' design-arounds and prior art could limit enforceability of the broadest claims; ongoing patent litigation and opposition proceedings warrant vigilance.
FAQs
Q1: What is the primary therapeutic focus of U.S. Patent 8,759,393?
A1: The patent targets kinase inhibition for treating cancers such as non-small cell lung cancer (NSCLC) and inflammatory diseases, focusing on heteroaryl substituted pyrazolopyrimidines.
Q2: How broad are the compound claims in this patent?
A2: The claims cover a wide range of derivatives with various heteroaryl groups and substituents at key positions, effectively capturing a large chemical space within kinase inhibitors.
Q3: Which jurisdictions have granted or pending patents for this invention?
A3: The U.S., Europe, Japan, and China, with active enforcement and granted patents in regions representing major pharmaceutical markets.
Q4: How does this patent landscape compare with competitors' patents?
A4: It has considerable overlap with other kinase inhibitor patents, necessitating careful freedom-to-operate assessments and potential design-arounds.
Q5: What strategies could competitor companies employ to challenge or circumvent this patent?
A5: Developing derivatives outside the patent’s claim scope, focusing on different kinases, or exploiting specific claim limitations through chemical modifications.
References
- U.S. Patent 8,759,393. (2014).
- WO 2012/090002. AstraZeneca.
- USPTO Public PAIR. (Accessed 2023).
- European Patent Office (EPO). Patent documents and statuses.
- Johnson, B. et al. (2015). “Kinase Inhibitors in Oncology: Patent Strategy and Landscape,” J. Pharm. Pat. 7(2): 123-135.
This comprehensive analysis supports strategic decision-making related to patents, competition, and licensing within the kinase inhibitor therapeutics landscape.
More… ↓
⤷ Start Trial
|
